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Beta-Adrenergic Blocking Agents
or Angiotensin-Converting
Enzyme Inhibitors, or Both, for
Postinfarction Patients With Left
Ventricular Dysfunction*
ROBERT A. O’ROURKE, MD, FACC
San Antonio, Texas
The use of pharmacologic agents for the secondary prevention
of sudden and non-sudden death and recurrent myocardial
infarction (MI) in patients who survive an acute MI has proved
to be effective in a large number of multicenter, randomized
clinical trials and is now commonplace. Drugs frequently used
for this purpose include aspirin, beta-adrenergic blocking
agents, angiotensin-converting enzyme (ACE) inhibitors and,
more recently, lipid-lowering agents (1–10).
Whether the beneficial effects of multiple-drug therapy for
secondary prevention are additive in various groups of postin-
farction patients is an important question. This is particularly
true concerning the combined use of beta-blocking drugs and
ACE inhibitors in high risk patients, particularly in those with
depressed left ventricular (LV) systolic function.
Beta-adrenergic receptor blockers. The long-term benefit
of beta-adrenergic receptor blockade in the secondary preven-
tion of death after MI has been demonstrated in several
randomized clinical trials (3–5). Although most of the salutary
effects of beta-blockers occur within the first week of infarc-
tion, continuing reduction in mortality has been documented
for up to 6 years (11).
Mechanisms by which beta-blockers may be efficacious
include, among others, a reduction in the arrhythmogenic and
myocardial ischemic effects of catecholamines. The salutary
effects of long-term beta-blocker therapy are most marked in
high risk patients, such as those with depressed LV systolic
function (12). Unfortunately, beta-blockers are underutilized
in patients with impaired LV performance after acute MI, even
though these patients have the most to gain from such treat-
ment (13). Furthermore, it has been uncertain whether these
agents confer additional benefit to patients with asymptomatic
LV dysfunction who are also being treated with an ACE
inhibitor.
Beneficial effects of ACE inhibitors. Angiotensin-convert-
ing enzyme inhibitors are beneficial in selected patients who
have recovered from an acute infarction because of their ability
to interfere with ventricular remodeling and thus attenuate
ventricular dilation over time. The clinical result is a lesser
incidence of the development of congestive heart failure,
recurrent myocardial infarction and death (14).
Nine trials with a cumulative enrollment of .100,000
patients have documented the beneficial effect of ACE inhibi-
tion on mortality in a prospective, randomized manner (15).
Five of these trials studied the selective use of ACE inhibitors
in higher risk patients after acute myocardial infarction. In
SAVE (6) and TRACE (16), patients were selected by labo-
ratory evidence of an LV ejection fraction #40% or wall
motion abnormalities. In AIRE (7), heart failure was the entry
criterion. In SMILE (8) and CATS (17), the selection criterion
was anterior infarct location on the electrocardiogram. A
statistically significant mortality reduction of 40 to 70 lives
saved per 1,000 patients treated was documented in four of
these five trials (15). Thus, it would seem appropriate to
initiate therapy with ACE inhibitors, either limited to patients
at high risk or in a nonselective manner as long as no
contraindications exist, and then consider withdrawing the
drug later in patients who demonstrate a lack of high risk
characteristics (15). Some rationale exists for the long-term use
of these drugs in all patients after MI, and the results of this
approach are currently being studied in adequately designed
prospective clinical trials (18).
Neurohumoral activation in patients with acute MI. In
asymptomatic patients with LV systolic dysfunction, neuroen-
docrine activation often occurs before overt heart failure
ensues and is evident even in untreated patients (19,20).
Activation of neurohumoral systems occurs during the first few
days of an acute MI but generally subsides by hospital dis-
charge, except in certain patients taking diuretic drugs and in
many with LV dysfunction (21). In the neurohumoral substudy
of the SAVE trial (22), significantly higher levels of plasma
renin activity, aldosterone, norepinephrine, dopamine, argi-
nine vasopressin and atrial natriuretic peptide were found in
534 patients than in age-matched control subjects.
When various neurohumoral systems were considered as
activated or not, along with other variables known to modify
survival in a multivariate analysis, only activation of atrial
natriuretic peptide remained significantly related to 1-year
cardiovascular mortality (22). Both atrial natriuretic peptide
and plasma renin activity remained associated with total
cardiovascular mortality in the neurohumoral subgroup of
patients who were followed up for an average of 38 months.
Activation of arginine vasopressin continued to be related to
recurrent MI, whereas plasma renin activity, atrial natriuretic
peptide, arginine vasopressin and aldosterone were indepen-
dently related to the combined end point of recurrent MI,
severe heart failure or cardiovascular death. Thus, neurohu-
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moral activation at the time of hospital discharge in post-MI
patients appears to be an independent sign of poor prognosis
(21), particularly with plasma regard to renin activity and atrial
natriuretic peptide.
When considered together with other important variables,
the independent predictive value of plasma norepinephrine
remained significant only for the development of severe heart
failure and combined cardiovascular end points. This differs
from patients with chronic heart failure, where plasma norepi-
nephrine is a major predictor of subsequent mortality after
adjusting for other contributing factors (23).
Effects of ACE inhibitors on neurohumoral activation. The
salutary effects of ACE inhibitors in patients with chronic heart
failure has been greatest in those with the most neurohumoral
activation, particularly of the renin-angiotensin system (20,24).
However, in the neurohumoral substudy of the SAVE trial,
captopril had little effect on the prognostic value of neurohor-
mone levels on any of the measured end points, except for
slightly modifying the prognostic value of plasma renin activity
and arginine vasopressin on 1-year cardiovascular mortality
(22). Low statistical power due to an inadequate sample size in
the SAVE neurohumoral substudy is a possible explanation.
Alternatively, activation of the renin system may be particu-
larly deleterious in the first year after MI, or early post-MI high
levels may not accurately reflect long-term activation of this
system. Finally, the benefits may be due to ACE inhibitor-
related effects that are not necessarily reflected by levels of
circulating plasma renin activity (22).
Relation of neurohumoral activation and beta-blocker effi-
cacy. In this issue of the Journal, Vantrimpont et al. (25)
present a retrospective analysis of the relation between beta-
blocker use at the time of randomization, neurohumoral
activation and the subsequent development of cardiovascular
events in the neurohumoral substudy group from the SAVE
study. Beta-blockers had no greater beneficial effect in patients
with neurohumoral activation, with the exception of atrial
natriuretic peptide. Interestingly, neurohumoral activation of
norepinephrine and aldosterone actually appeared to reduce
the efficacy of beta-blockers in postinfarction patients.
In the SAVE population, neurohumoral activation did not
identify patients who would benefit most from long-term
treatment with a beta-blocker. Possibly, neurohumoral activa-
tion may be an indicator of disease severity, whereas the
beneficial effects of beta-blockers may be due to other mech-
anisms. Perhaps, the unspecified doses of beta-blockers used
were insufficient to prevent the harmful effects of norepineph-
rine in patients with activation of the sympathetic nervous
system (25). Also, plasma norepinephrine concentrations may
underestimate cardiac sympathetic activation, which is known
to be elevated in patients with severe LV dysfunction. Further-
more, a single determination of neurohumoral activity per-
formed at rest early after MI may not reflect long-term
neurohumoral activation after MI. Again, the possibility of low
statistical power due to inadequate sample size and small
number of events must be considered (25).
Additive effects of beta-blockers and ACE inhibitors in
postinfarction patients with LV dysfunction. In the entire
SAVE population of 2,231 patients, the use of beta-blockers in
789 was significantly associated with lower 1-year cardiovascu-
lar mortality, total cardiovascular mortality, incidence of se-
vere heart failure and occurrence of the combined end point.
Use of beta-blockers was associated with a lower risk of a
recurrent MI that did not reach statistical significance. Al-
though a quantitatively similar decrease in risk was associated
with beta-blocker use in the neurohumoral group, only the
reductions of 1-year cardiovascular mortality, total cardiovas-
cular mortality and development of severe heart failure were
statistically significant, most likely because of the small number
of patients and, thus, wider confidence intervals (25).
More important, in the total SAVE population, when the
use of beta-blockers was considered with other variables
influencing prognosis (including randomization to captopril),
the favorable influence of beta-blockers remained significant,
albeit somewhat smaller. In the neurohumoral subpopulation,
the reductions in risk due to the use of beta-blockers were not
statistically significant, perhaps because of the small number of
events in proportion to the number of independent variables
used in the multivariate analyses. In the SAVE study, the use
of beta-blockers in post-MI patients with LV systolic dysfunc-
tion was associated with an independent decrease in cardio-
vascular mortality and reduction in the incidence of severe
heart failure. Beta-blocker treatment was associated with a
26% reduction in 1-year cardiovascular mortality and a 30%
reduction in cardiovascular mortality over the length of the
study. These results are consistent with the findings of previous
randomized trials.
Thus, the current report by Vantrimpont et al. (25) suggests
that the beneficial effects of beta-blockers and ACE inhibitors
on hard cardiovascular end points are additive during an
average follow-up period of 42 months in patients with a LV
ejection fraction #40% after an acute MI. The previously
reported salutary effects of beta-blocker therapy in post-MI
patients with impaired LV systolic function are confirmed and
strengthened by the current study; improved survival occurs in
patients whose short- and long-term prognosis due to LV
dysfunction is also enhanced by the use of ACE inhibitors.
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